A unique functional subset of CCL19-expressing dendritic cells has been identified, showing favorable responses to anti-PD-1 therapy and displaying migratory and immunomodulatory phenotypes in triple-negative breast cancer [36]. The gene discussed is CCL19; the disease is triple-negative breast carcinoma.